Expanded Use of Vorasidenib in Non-Enhancing Recurrent CNS WHO Grade 3 Oligodendroglioma

Expanded Use of Vorasidenib in Non-Enhancing Recurrent CNS WHO Grade 3 Oligodendroglioma

<b>Background/Objectives</b>: Anaplastic oligodendrogliomas (AOs) are central nervous system (CNS) World Health Organization (WHO) grade 3 gliomas characterized by isocitrate dehydrogenase (IDH) mutation (m)IDH and 1p/19q codeletion. AOs are typically treated with surgery and chemoradiat...

Full description

Saved in:
Bibliographic Details
Main Authors: Alexander S. Himstead, Jefferson W. Chen, Eleanor Chu, Mari A. Perez-Rosendahl, Michelle Zheng, Sherin Mathew, Carlen A. Yuen
Format: Article
Language:English
Published: MDPI AG 2025-01-01
Series:Biomedicines
Subjects:
vorasidenib
anaplastic oligodendroglioma
isocitrate dehydrogenase
IDH inhibitor
glioma
Online Access:https://www.mdpi.com/2227-9059/13/1/201
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/2227-9059/13/1/201

Similar Items